Keywords: Halozyme, Pfizer, Biologics, Enhanze technology, rHuPH20

Halozyme Thera in $500 million-plus deal with Pfizer for biologics

Article | 24 December 2012

Print This

US biotech Halozyme Therapeutics (Nasdaq: HALO) saw its shares leap 27% to $7.01 by close of trading last Friday, when the company ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in